Femasys (NASDAQ:FEMY – Get Free Report) and NeoGenomics (NASDAQ:NEO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.
Earnings and Valuation
This table compares Femasys and NeoGenomics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Femasys | $1.63 million | 16.69 | -$18.82 million | ($0.86) | -0.97 |
| NeoGenomics | $709.16 million | 1.90 | -$78.73 million | ($0.88) | -11.85 |
Analyst Ratings
This is a summary of current ratings and price targets for Femasys and NeoGenomics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Femasys | 1 | 0 | 3 | 0 | 2.50 |
| NeoGenomics | 1 | 8 | 7 | 0 | 2.38 |
Femasys presently has a consensus target price of $7.33, suggesting a potential upside of 778.24%. NeoGenomics has a consensus target price of $13.11, suggesting a potential upside of 25.71%. Given Femasys’ stronger consensus rating and higher probable upside, research analysts clearly believe Femasys is more favorable than NeoGenomics.
Risk and Volatility
Femasys has a beta of -2.55, suggesting that its share price is 355% less volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.
Institutional & Insider Ownership
65.3% of Femasys shares are owned by institutional investors. Comparatively, 98.5% of NeoGenomics shares are owned by institutional investors. 11.5% of Femasys shares are owned by company insiders. Comparatively, 2.4% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Femasys and NeoGenomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Femasys | -1,113.72% | -713.74% | -152.60% |
| NeoGenomics | -16.00% | -3.36% | -1.95% |
About Femasys
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
About NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
